These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30858682)

  • 1. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
    Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
    Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
    Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
    Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
    Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
    Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.
    Meerovitch K; Torkildsen G; Lonsdale J; Goldfarb H; Lama T; Cumberlidge G; Ousler GW
    Clin Ophthalmol; 2013; 7():1275-85. PubMed ID: 23836957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial.
    Gioia N; Gerson J; Ryan R; Barbour K; Poteet J; Jennings B; Sharp M; Lowery R; Wilson J; Morde A; Rai D; Padigaru M; Periman LM
    Front Ophthalmol (Lausanne); 2024; 4():1362113. PubMed ID: 38984118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease.
    Baratta RO; Schlumpf E; Del Buono BJ; DeLorey S; Ousler G; Calkins DJ
    Ophthalmol Sci; 2024; 4(3):100451. PubMed ID: 38317866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
    Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
    Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
    Clark D; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
    Evans D; Kenyon K; Ousler G; Watson M; Vollmer P; McLaurin EB; Torkildsen G; Winters J; Dodd J; Jordan R; Wills ST; Spana C
    J Ocul Pharmacol Ther; 2023 Nov; 39(9):600-610. PubMed ID: 37677000
    [No Abstract]   [Full Text] [Related]  

  • 12. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
    Tauber J; Schechter BA; Bacharach J; Toyos MM; Smyth-Medina R; Weiss SL; Luchs JI
    Clin Ophthalmol; 2018; 12():1921-1929. PubMed ID: 30323548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
    Sosne G; Ousler GW
    Clin Ophthalmol; 2015; 9():877-84. PubMed ID: 26056426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.
    Goldstein MH; Martel JR; Sall K; Goldberg DF; Abrams M; Rubin J; Sheppard J; Tauber J; Korenfeld M; Agahigian J; Durham TA; Furfine E
    Eye Contact Lens; 2017 Sep; 43(5):287-296. PubMed ID: 27466718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.